FTC Orders Illumina to Divest Cancer Detection Test Maker Grail

The US Federal Trade Commission on Monday ordered Illumina to divest cancer diagnostic test maker Grail, finding that its ownership would stifle competition in the US market for cancer tests.
Reuters Health Information

source https://www.medscape.com/viewarticle/990377?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?